Introduction. Currently, α-blockers (α-AB) and 5-alpha-reductase inhibitors (I-5-AR) are recommended as the drugs of choice for the treatment of patients with benign prostatic hyperplasia (BPH). However, despite the clear advantages of combination therapy, at the initial stages of treatment, I-5-AR is either not prescribed at all, or added to therapy after a few months.
The aim of our study is to study the effectiveness of early and various options for delayed combined drug therapy of patients with BPH using α-AB and I-5-AR. Materials and methods. The study included 90 patients with BPH, who were divided into three groups of 30 people. In group 1, monotherapy with drugs from the α-AB group was performed for 6 months, after which they were transferred to treatment with a combined drug. In group 2, monotherapy was performed for three months, after which they were also transferred to treatment with a combined drug. And in group 3, patients were prescribed combination therapy
from day 1.
Results. Early combination therapy with dutasteride was more effective than delayed Therapy for 6 months. There were no significant differences in the main parameters studied between patients who simultaneously started combination therapy and switched to it after 3 months, by the end of the 12th month of treatment. However, early therapy is a combined drug made it possible to achieve a more rapid effect in relation
to LUTS.
Conclusion. Thus, the data obtained confirm the clinical recommendations regarding the expediency of early initiation of combined therapy with an α-adrenoblocker and a 5α-reductase inhibitor in patients with moderate and severe LUTS caused by BPH and the risk of disease progression. Postponing the transition to combination therapy for 6 months or more may lead to a decrease in the effectiveness of treatment of patients in this category.

Keywords: inhibitors of 5-alpha-reductase and alpha-blockers, Duodart, BPH, benign prostatic hyperplasia